Levetiracetam Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0038/G 
This was an application for a group of variations. 
19/06/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0037 
B.III.1.a.2 - Submission of a new/updated or 
31/10/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0036 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/07/2022 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
SmPC, 
Labelling and 
PL 
IB/0035 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/05/2021 
17/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0034/G 
This was an application for a group of variations. 
03/05/2021 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
Page 2/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
IA/0033 
A.7 - Administrative change - Deletion of 
15/02/2021 
17/06/2021 
Annex II and 
manufacturing sites 
PL 
IB/0032/G 
This was an application for a group of variations. 
11/01/2021 
17/06/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0031/G 
This was an application for a group of variations. 
11/06/2020 
n/a 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
Page 3/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0030 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/01/2020 
10/08/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0029/G 
This was an application for a group of variations. 
25/09/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
Page 4/13 
 
 
 
 
 
 
 
 
 
 
 
from an already approved manufacturer 
IB/0028 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/09/2019 
10/08/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0027 
B.II.b.1.a - Replacement or addition of a 
13/11/2018 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0026 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/10/2018 
29/10/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0025 
Minor change in labelling or package leaflet not 
31/01/2018 
29/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0024 
B.II.b.3.a - Change in the manufacturing process of 
21/12/2017 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/02/2017 
11/01/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 5/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
R/0021 
Renewal of the marketing authorisation. 
26/05/2016 
15/07/2016 
SmPC, Annex 
II, Labelling 
and PL 
IA/0022 
A.7 - Administrative change - Deletion of 
30/03/2016 
15/07/2016 
Annex II and 
manufacturing sites 
PL 
IB/0020 
B.I.b.2.e - Change in test procedure for AS or 
13/11/2015 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0019/G 
This was an application for a group of variations. 
14/10/2015 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
Page 6/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
corresponding test method 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
T/0018 
Transfer of Marketing Authorisation 
09/01/2015 
03/02/2015 
SmPC, 
Labelling and 
PL 
IB/0016 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
30/07/2014 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IAIN/0013/G 
This was an application for a group of variations. 
25/07/2014 
n/a 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
Page 7/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0017 
B.I.b.z - Change in control of the AS - Other 
22/07/2014 
n/a 
variation 
IB/0015 
B.I.b.2.e - Change in test procedure for AS or 
22/07/2014 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0014 
B.I.b.2.e - Change in test procedure for AS or 
22/07/2014 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0012 
To delete ‘swallow tablets whole’ from section 5 of 
01/07/2014 
27/01/2015 
Labelling 
labelling PARTICULAR TO APPEAR ON THE OUTER 
PACKAGING’. Furthermore the MAH took this 
Page 8/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
opportunity to correct errors in Bulgarian, Italian, 
Danish, Hungarian, German and Swedish annexes. 
In addition the wording/orthography of the SmPC 
and/or PIL is being brought in line with the originator 
for BG, IT, HR, CZ, FI, DE, DK, EL, HU, LT, PT, SL, 
ES, NO. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IB/0011/G 
This was an application for a group of variations. 
28/03/2014 
27/01/2015 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0010 
C.I.2.z - Change in the SPC, Labelling or PL of a 
03/01/2014 
27/01/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Other variation 
IAIN/0009/G 
This was an application for a group of variations. 
24/06/2013 
n/a 
Page 9/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
IB/0008/G 
This was an application for a group of variations. 
30/10/2012 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.c.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Other variation 
B.I.c.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Other variation 
B.I.c.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Other variation 
B.I.c.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Other variation 
IAIN/0007 
B.II.b.2.b.1 - Change to batch release arrangements 
23/08/2012 
31/10/2012 
Annex II and 
Page 10/13 
 
 
 
 
 
 
 
 
 
 
 
 
and quality control testing of the FP - Not including 
PL 
batch control/testing 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/07/2012 
31/10/2012 
SmPC, Annex 
Update of the product information to be in line with the 
generic/hybrid/biosimilar products following 
II, Labelling 
reference product (Keppra II-131), The SmPC was updated 
assessment of the same change for the reference 
and PL 
in order to add 'panic attack' as an undesirable effect 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
following the cumulative review of the safety data for 
Keppra. The Package Leaflet was updated in accordance. In 
addition, the description of pancytopenia, erythema 
multiforme, Stevens-Johnsons syndrome and toxic 
epidermal necrolysis in section 4 of the Package Leaflet was 
updated.  
Furthermore, the product information was brought in line 
with the latest QRD template, version 8. 
IA/0005 
B.II.b.3.a - Change in the manufacturing process of 
12/06/2012 
n/a 
the finished product - Minor change in the 
manufacturing process of an immediate release solid 
oral dosage form or oral solutions 
IB/0004 
B.II.b.1.e - Replacement or addition of a 
13/04/2012 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/03/2012 
11/06/2012 
SmPC and PL 
On 5 January 2012, the MAH received a notification from 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
the Agency requesting the submission of a variation for 
Levetiracetam Teva. This variation is to update section 4.8 
of the SmPC and section 4 of the PIL as a consequence of 
the adoption by the CHMP of safety variations related to 
significant modifications of the Summary of Product 
Page 11/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0002 
A.5.a - Administrative change - Change in the name 
06/01/2012 
11/06/2012 
Annex II and 
and/or address of a manufacturer responsible for 
PL 
batch release 
IB/0001/G 
This was an application for a group of variations. 
28/11/2011 
11/06/2012 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
Characteristics due in particular to new quality, pre-clinical, 
clinical or pharmacovigilance data to the reference 
medicinal product Keppra. 
In addition, the MAH has taken this opportunity to correct 
local representatives in the package leaflet for Austria, 
Germany, Estonia, Italy, Norway and Finland in all 
languages. 
Further corrections have been made in languages for 
Greece, Estonia, France, Iceland, Italy, Portugal, Romania 
and Slovenia in line with the reference medicinal product. 
Page 12/13 
 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
Page 13/13 
 
 
 
 
 
 
 
